Table 3.

CAT of all subjects at baseline and follow-up visits.

	The conventional treatment group (n = 30)	The vaccination strategy group (n = 31)	The oral probiotics group (n = 27)	The aerosol inhaled amikacin group (n = 24)	p value*
Baseline	19.32 ± 9.13	19.95 ± 6.08	20.31 ± 7.14	21.71 ± 4.46	0.753
3-month visit	18.37 ± 8.82	18.8 ± 6.58	19.13 ± 8.71	19.36 ± 8.24	0.986
6-month visit	18.16 ± 7.04	18.23 ± 5.5	19.38 ± 5.74	18.64 ± 6.25#	0.935
12-month visit	18.53 ± 6.64	18.9 ± 5.42	20.44 ± 7.0	19.29 ± 6.10	0.821

Data are shown as means ± standard deviation. *p value was derived from comparison among groups. ^#p value < 0.05 (self-control paired t test).